Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45.